Value-based insurance plus disease management increased medication use and produced savings

Health Affairs

Volumn 30, Issue 1, 2011, Pages 100-108

  Gibson, Teresa B ^a   Mahoney, John ^b   Ranghell, Karlene ^b   Cherney, Becky J ^b   McElwee, Newell ^c  

^a THOMSON REUTERS   (United States)

^b Florida Health Care Coalition   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; ORAL ANTIDIABETIC AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; COST CONTROL; DIABETES MELLITUS; DRUG COST; DRUG USE; DRUG UTILIZATION; FEMALE; HEALTH INSURANCE; HEALTH PROGRAM; HUMAN; INVESTMENT; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRESCRIPTION;

COST SAVINGS; DEDUCTIBLES AND COINSURANCE; DIABETES MELLITUS; DISEASE MANAGEMENT; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSURANCE, HEALTH; MALE; MIDDLE AGED; MODELS, ECONOMETRIC; PATIENT COMPLIANCE;

EID: 79951597073     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2010.0896     Document Type: Article

References (19)

1. Houy M. Value-based benefit design: a purchaser guide [Internet]. Washington (DC): National Business Coalition on Health; 2009 Jan [cited 2010 Aug 26]. Available from: http://www.sph.umich.edu/ vbidcenter/publications/pdfs/ VBBDPurchaserGuide% 5B1%5D.pdf
2. Fendrick AM, Chernew ME. Value-based insurance design: aligning incentives to bridge the divide between quality improvement and cost containment. Am J Manag Care. 2006;12(Spec. no.):SP5-10.
3. American Diabetes Association. Diabetes statistics [Internet]. Alexandria (VA): The Association; [cited 2010 Aug 21]. Available from: http:// www.diabetes.org/diabetes-basics/ diabetes-statistics/
4. Chernew ME, Shah MR, Wegh A, Rosenberg SN, Juster IA, Rosen AB, et al. Impact of decreasing copayments on medication adherence within a disease management environment. Health Aff (Millwood). 2008;27(1):103-12. (Pubitemid 351198595)
5. Zeng F, Jin JA, Scully R, Barrington C, Patel BV, Nichol MB. The impact of value-based benefit design on adherence to diabetes medications: a propensity score-weighted difference in difference evaluation. Value Health. 2010;13(6):846-52.
6. Chang A, Liberman JA, Coulen C, Berger JE, Brennan TA. Value-based insurance design and antidiabetic medication adherence. Am J Pharm Benefits. 2010;2(1):39-45.
7. Claxton G, DiJulio B, Finder B, Lundy J, McHugh M, Osel-Anto A, et al. Employer health benefits: 2009 annual survey [Internet]. Menlo Park (CA): Kaiser Family Foundation; 2009 [cited 2010 Nov 12]. Available from: http://ehbs.kff.org/ pdf/2009/7936.pdf
8. Mattke S, Seid M, Ma S. Evidence for the effect of disease management: is $1 billion a year a good investment? Am J Manag Care. 2007;13(12):670-6.
9. Piette J. The future of diabetes disease management: integrating lessons learned from clinical, health services, and policy research. Am J Manag Care. 2005;11(4):203-5. (Pubitemid 40569743)
10. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy; a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193-203.
11. National Committee for Quality Assurance. Comprehensive diabetes care [Internet]. Washington (DC); NCQA; 2008 Oct [cited 2010 Nov 29]. (HEDIS 2009 technical update). Available from: http:// www.ncqa.org/Portals/0/Policy Updates/HEDIS%20Technical% 20Updates/09-CDC-Spec.pdf
12. Thomson Reuters. Advantage Suite - employers [Internet]. New York (NY): Thomson Reuters; [cited 2010 Nov 29]. Available from: http:// thomsonreuters.com/products- services/healthcare/healthcare- products/a-z/advantage-suite- employers
13. To access the Appendix, click on the Appendix link in the box to the right of the article online.
14. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41-55.
15. D'Hoore W, Bouckaert A, Tilquin C. Practical considerations on the use of the Charlson Comorbidity Index with administrative data bases. J Clin Epidemiol. 1996;49:1429-33. (Pubitemid 27028932)
16. Ashcraft ML, Fries BE, Nerenz DR, Falcon SP, Srivastava SV, Lee CZ, et al. A psychiatric patient classification system: an alternative to diagnosis- related groups. Med Care. 1989;27(5):543-57.
17. Ho PM, Rumsfeld JS, Masoudi FA, McClure DL, Plomondon ME, Steiner JF, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med. 2006;166(17):1836-41. (Pubitemid 44455165)
18. Choudhry NK, Shrank WH, Levin RL, Lee JL, Jan SA, Brookhart MA, et al. Measuring concurrent adherence to multiple related medications. Am J Manag Care. 2009;15(7):457-64.
19. Services for diabetes were those that had an International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), diagnosis code of 250.xx, 357.2, 362.0x, 366.41, 337.1x, 357.2x, 648.0, or 713.5x, where x is any digit 0 through 9 that represents a valid diagnosis code.